Telix Pharmaceuticals (ASX:TLX) said the first patient has been administered its drug candidate TLX300-CDx in the Phase 1 ZOLAR1 trial for advanced metastatic soft tissue sarcoma (STS), according to a Tuesday statement by the company.
The trial aims to assess the drug's biodistribution, safety, and optimal dose using positron emission tomography (PET), the statement said.
TLX300-CDx targets PDGFRα, a protein often over-expressed in STS, the statement added.
The study will inform future therapeutic approaches for treating the disease, the company said.
Telix holds the rights to develop and commercialize the radiolabelled drug, the company added.
Shares of the company fell 3% on market close.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。